Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7624 in Corticosteroid Resistant Asthma
NCT02753764Phase 2Completed
- Sponsor
- National Jewish Health
- Start
- Jan 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD7624 in asthma (4 arms), sponsored by National Jewish Health. Primary endpoints: P38 MAPK activation in whole blood samples at 4 months and P38 MAPK activation in BAL and induced sputum macrophages at 4 months. Started Jan 2017; status: completed.
02
Drugs
AZD7624
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02753764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753764.